skip to Main Content

Comparison of 4- and 4 plus-courses S-1 Administration as Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma

Newsfeed image, light gray text on dark gray background
Data were retrospectively collected from consecutive patients who underwent S-1 adjuvant chemotherapy following curative pancreatectomy between January 2016 and December 2018.

Four-courses and > 4 courses cohorts were compared for overall survival (OS) as a primary outcome, and relapse-free survival (RFS) and adverse event incidence as secondary outcomes. Read more . . . 

Back To Top